Amoxicillin — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Acute Bacterial Sinusitis

• Doxycycline
• Doxycycline 100 mg tabs

Also listed for Acute Otitis Media/Externa (Ear Infection)

• Ciprofloxacin-dexamethasone otic

Also listed for Bacterial Infections

• Azithromycin
• Ciprofloxacin
• Levofloxacin
• Metronidazole

Also listed for Chronic Sinusitis

• Cetirizine

Other medications in Infectious Disease

• Bictegravir/Emtricitabine/TAF
• Dolutegravir/Lamivudine
• Elbasvir/Grazoprevir
• Emtricitabine/Tenofovir
• Glecaprevir/Pibrentasvir
• Molnupiravir
• Nirmatrelvir/Ritonavir
• Nitrofurantoin

What Amoxicillin is approved for (FDA label)

Amoxicillin is a penicillin-class antibacterial indicated for treatment of infections due to susceptible strains of designated microorganisms.

Source: Read the full FDA label on DailyMed. Label effective date: September 9, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Amoxicillin (FDA label)

Amoxicillin capsules, USP: blue and pink capsule 500 mg. Each capsule of amoxicillin, with royal blue opaque cap and pink opaque body, contains 500 mg of amoxicillin as the trihydrate. The cap and body of the of the 500 mg capsule are imprinted with "AMOXIL ® " over "500". Capsules: 500 mg

Source: FDA prescribing information (DailyMed). Set ID: 4adc198e-39d8-4b3e-bfa4-278aaf4064ae. SPL document ID: 5b0d4963-eecd-294e-e063-6294a90a87b4. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Amoxicillin (FDA label)

The following are discussed in more detail in other sections of the labeling: Anaphylactic reactions [see Warnings and Precautions ( 5.1 )] Drug-Induced Enterocolitis Syndrome (DIES) [see Warnings and Precautions ( 5.2 )] CDAD [see Warnings and Precautions ( 5.3 )] The most common adverse reactions (> 1%) observed in clinical trials of amoxicillin capsules, tablets or oral suspension were diarrhea, rash, vomiting, and nausea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact USAntibiotics, LLC at 1-844-454-5532 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 4adc198e-39d8-4b3e-bfa4-278aaf4064ae. SPL document ID: 5b0d4963-eecd-294e-e063-6294a90a87b4. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Amoxicillin (FDA label)

Amoxicillin is contraindicated in patients who have experienced a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin or to other ​ β‑lactam antibiotics (e.g., penicillins and cephalosporins). History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to Amoxicillin or to other beta-lactams (e.g., penicillins or cephalosporins) ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 4adc198e-39d8-4b3e-bfa4-278aaf4064ae. SPL document ID: 5b0d4963-eecd-294e-e063-6294a90a87b4. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Amoxicillin (FDA label)

Anaphylactic reactions: Serious and occasionally fatal anaphylactic reactions have been reported in patients on penicillin therapy. Serious anaphylactic reactions require immediate emergency treatment with supportive measures. ( 5.1 ) Drug-induced enterocolitis syndrome (DIES) has been reported with amoxicillin use. If this occurs, discontinue Amoxicillin and institute appropriate therapy. ( 5.2 ) Clostridium difficile -associated diarrhea (ranging from mild diarrhea to fatal colitis): Evaluate if diarrhea occurs. ( 5.3 ) 5.1 Anaphylactic Reactions Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy including amoxicillin. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins.

Source: FDA prescribing information (DailyMed). Set ID: 4adc198e-39d8-4b3e-bfa4-278aaf4064ae. SPL document ID: 5b0d4963-eecd-294e-e063-6294a90a87b4. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Amoxicillin (FDA label)

Probenicid decreases renal tubular secretion of amoxicillin which may result in increased blood levels of amoxicillin. ( 7.1 ) Concomitant use of amoxicillin and oral anticoagulants may increase the prolongation of prothrombin time. ( 7.2 ) Coadministration with allopurinol increases the risk of rash. ( 7.3 ) Amoxicillin may reduce the efficacy of oral contraceptives. ( 7.4 ) 7.1 Probenecid Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use of amoxicillin and probenecid may result in increased and prolonged blood levels of amoxicillin. 7.2 Oral Anticoagulants Abnormal prolongation of prothrombin time (increased international normalized ratio [INR]) has been reported in patients receiving amoxicillin and oral anticoagulants. Appropriate monitoring should be undertaken when anticoagulants are prescribed concurrently.

Source: FDA prescribing information (DailyMed). Set ID: 4adc198e-39d8-4b3e-bfa4-278aaf4064ae. SPL document ID: 5b0d4963-eecd-294e-e063-6294a90a87b4. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.